About Fabric Genomics
Fabric Genomics is making precision medicine a reality by facilitating clinical labs, hospital systems, and country-sequencing programs to develop, deploy, and scale genomic testing. The company's flagship Fabric Enterprise platform leverages advanced AI algorithms to automate genomic data interpretation and generate physician-ready clinical reports for any genomic test. Fabric's technology addresses the major bottleneck in genetic testing: interpretation and report generation as test volumes rapidly increase. The platform combines deep phenotype data with genotype data using machine learning to accurately identify and prioritize disease-causing variants in rare idiopathic diseases. Fabric's AI approach includes proprietary algorithms such as GEM, VAAST, Phevor, and VVP that systematically prioritize variants based on severity in conjunction with patient phenotype. The company serves children's hospitals, hospital systems, and commercial laboratories worldwide, supporting applications including hereditary risk screening, rare disease diagnosis, rapid NICU testing, pediatric panels, and country genome projects. Fabric's cloud-based solution can scale from a single test to hundreds of thousands while maintaining high accuracy and rapid turnaround times. The company has achieved diagnostic yields up to 50% compared to the industry average of 25-30%, with the ability to generate clinical reports in less than two hours for whole genome sequence data. In a significant milestone, GeneDx acquired Fabric Genomics to expand decentralized, AI-powered testing at global scale.
Mission & Story
Mission
Making precision medicine a reality by facilitating clinical labs, hospital systems, and country-sequencing programs to develop, deploy, and scale genomic testing
Clinical Focus
Medical conditions and clinical areas addressed by Fabric Genomics.
Who It Serves
Milestones & Awards
Recent Milestones
GeneDx acquired Fabric Genomics to expand decentralized, AI-powered testing at global scale; Oxford Nanopore and Fabric Genomics launched integrated WGS Pediatric Care Solution for long-read WGS in NICU/PICU applications; PlumCare and Fabric announced strategic partnership integrating AI with FirstSteps newborn genome screening program in Greece
Key Partnerships
Social & Media
Follow on
Latest Updates
ASHG 2025, October 14–18, 2025, Boston
ICoNS 25, October 23–24, 2025, London
GeneDx to Acquire Fabric Genomics, Enabling Decentralized, AI-Powered Testing at Global Scale
GeneDx Announces Completion of Fabric Genomics Acquisition
AGBT Precision Health, Sept 8–10, 2025, Loews Coronado Bay Resort (San Diego)
Company Details
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 60 →
23andMe
23andMe uses AI to analyze genetic data and provide personalized health summaries, risk assessments, and wellness recommendations based on genomic insights.
2bPrecise
AI-powered precision medicine platform for personalized treatment recommendations and genomic analysis.
ACT Genomics
AI-powered genomic analysis platform for precision medicine and personalized treatment recommendations.
Adaptive Biotechnologies
Adaptive Biotechnologies uses AI and machine learning to decode the immune system and identify disease-specific immune signatures for diagnosis and personalized treatment.
Ambry Genetics
Ambry Genetics is a leading clinical genetic testing laboratory specializing in hereditary cancer, rare disease, cardiology, and neurology testing. The company provides advanced genetic testing solutions with paired DNA/RNA analysis and comprehensive patient support programs.
Ataraxis
Ataraxis develops AI-native precision medicine tools that predict patient outcomes and treatment response in oncology. Their flagship product, Ataraxis Breast, provides clinically validated prognostic and predictive tests for breast cancer using multi-modal AI analysis of pathology images and clinical data.
Avenda Health
Avenda Health develops Unfold AI, an FDA-cleared artificial intelligence platform that creates 3D cancer estimation maps for prostate cancer. The technology analyzes standard-of-care data (MRI, biopsy, pathology, PSA) to visualize cancer location and extent, helping physicians make more informed treatment decisions and improve patient outcomes.
Base Genomics
Base Genomics appears to be a company in the Precision Medicine & Genomics space, but the scraped website content is empty or inaccessible, preventing detailed analysis of their offerings and target market.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.